Baiyang Zhixin Medical Research

Baiyang Zhixin Medical Research is a Chinese biotechnology company focused on the translation of cutting-edge cardiovascular technologies and the development of original drugs. Operating as a cardiovascular innovation platform under Baheal Group, the company leverages its proprietary human primary cardiomyocyte disease model platform to discover novel therapeutic targets and validate drug efficacy. Its lead candidate, YY524051, is a first-in-class small molecule inhibitor targeting a JUN-related downstream pathway, currently in Phase 1 clinical development for heart failure with preserved ejection fraction (HFpEF). Baiyang Zhixin aims to bridge the gap between basic laboratory research and clinical application to address significant unmet medical needs in cardiovascular medicine.